Cardiac resynchronization therapy with defibrillator (CRT-D) has demonstrated advantages over implantable cardioverter defibrillator (ICD) in terms of morbidity, symptom reduction, and survival. But there is no exact data indicating benefit of adding an ICD in CRT-indicated patients, despite theoretically decreased risk of death due to arrhythmia with this combination (1). Despite the lack of evidence, CRT-D is preferred over cardiac resynchronization therapy with pacemaker (CRT-P) without any strict recommendation. Here we would like to share our experience, which also favors CRT-D over CRT-P, but for another reason: pacing site-dependent arrhythmia.
